Bictegravir news

All news on Bictegravir (also known as GS-9883): plants, production capacities, investments and involved companies.

15 October 2025
Merck Reports Phase 3 Trial Data on Doravirine-Islatravir Regimen
Phase 3 trials show minimal weight, body composition, and lipid changes with the DOR/ISL regimen in HIV-1 patients, maintaining viral suppression without resistance.

Who will be producing Bictegravir in the future?

Find out with chemXplore Analytics